Novo Nordisk

305.80 DKK

+0.66 %

Less than 1K followers

NOVO B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

+0.66 %

-3.01 %

-15.17 %

-35.85 %

-51.01 %

-60.91 %

-31.82 %

+48.14 %

+24,462.25 %

Novo Nordisk is a producer of insulin for diabetes treatment. In addition to the specialist expertise in diabetes, the company produces drugs for hormone treatment as well as for hemophilia and bleeding disorders. The products are found on a global market and are sold under separate brands. Novo Nordisk was founded in 1923 and is headquartered in Bagsværd, Denmark.

Market cap

1.37T DKK

Turnover

1.88B DKK

Revenue

290.4B

EBIT %

44.19 %

P/E

13.49

Dividend yield-%

3.73 %

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

4/2

2026

Annual report '25

26/3

2026

General meeting '26

All

Press releases

ShowingAll content types

Regulatory press release11/25/2025, 11:24 AM

Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes

Regulatory press release11/24/2025, 11:20 AM

Novo Nordisk A/S: Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression

Regulatory press release11/17/2025, 1:58 PM

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release11/14/2025, 2:21 PM

Resolutions from the Extraordinary General Meeting of Novo Nordisk A/S

Regulatory press release11/13/2025, 10:38 PM

Novo Nordisk A/S: Candidate for the Board of Directors will not seek election

Regulatory press release11/11/2025, 1:39 PM

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Press release11/8/2025, 8:18 AM

Novo Nordisk will not increase its proposal to acquire Metsera, Inc.

Regulatory press release11/6/2025, 6:00 PM

Novo Nordisk announces agreement with the U.S. Administration to bring GLP-1s to more Americans at a lower cost

Press release11/5/2025, 9:30 PM

Novo Nordisk Wegovy® users achieved waist and BMI targets linked to improved health and low risk of obesity-related complications

Regulatory press release11/5/2025, 6:30 AM

Novo Nordisk's sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025; R&D pipeline progress continues

Press release11/4/2025, 2:31 PM

Novo Nordisk submits updated proposal to acquire Metsera, Inc.

Regulatory press release10/30/2025, 9:49 AM

Novo Nordisk submits proposal to acquire Metsera, Inc.

Regulatory press release10/21/2025, 12:02 PM

Notice convening an Extraordinary General Meeting of Novo Nordisk A/S

Regulatory press release10/21/2025, 11:56 AM

Novo Nordisk announces an Extraordinary General Meeting to be convened to elect new members of the Board of Directors

Press release10/15/2025, 12:30 PM

Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor zaltenibart (OMS906)

Regulatory press release10/9/2025, 10:00 AM

Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolio

Press release9/18/2025, 8:45 AM

Novo Nordisk A/S: Ozempic® reduces the risk of heart attack, stroke and death by 23% compared to dulaglutide in the first head-to-head real-world study

Press release9/17/2025, 9:05 PM

Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study

Press release9/16/2025, 10:00 AM

Novo Nordisk presents phase 3 data for next-generation amylin cagrilintide, leading to advancement into dedicated clinical programme

Press release9/15/2025, 10:03 PM

People taking Novo Nordisk’s Wegovy® experienced reduced food noise and boosted mental well-being

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.